Loss of function of ENT3 drives histiocytosis and inflammation through TLR-MAPK signaling.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
16 Nov 2023
Historique:
accepted: 24 08 2023
received: 05 04 2023
medline: 17 11 2023
pubmed: 22 9 2023
entrez: 22 9 2023
Statut: ppublish

Résumé

Histiocytoses are inflammatory myeloid neoplasms often driven by somatic activating mutations in mitogen-activated protein kinase (MAPK) cascade genes. H syndrome is an inflammatory genetic disorder caused by germ line loss-of-function mutations in SLC29A3, encoding the lysosomal equilibrative nucleoside transporter 3 (ENT3). Patients with H syndrome are predisposed to develop histiocytosis, yet the mechanism is unclear. Here, through phenotypic, molecular, and functional analysis of primary cells from a cohort of patients with H syndrome, we reveal the molecular pathway leading to histiocytosis and inflammation in this genetic disorder. We show that loss of function of ENT3 activates nucleoside-sensing toll-like receptors (TLR) and downstream MAPK signaling, inducing cytokine secretion and inflammation. Importantly, MEK inhibitor therapy led to resolution of histiocytosis and inflammation in a patient with H syndrome. These results demonstrate a yet-unrecognized link between a defect in a lysosomal transporter and pathological activation of MAPK signaling, establishing a novel pathway leading to histiocytosis and inflammation.

Identifiants

pubmed: 37738562
pii: 498039
doi: 10.1182/blood.2023020714
doi:

Substances chimiques

Mitogen-Activated Protein Kinases EC 2.7.11.24
Toll-Like Receptors 0
SLC29A3 protein, human 0
Nucleoside Transport Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1740-1751

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2023 by The American Society of Hematology.

Auteurs

Ruth Shiloh (R)

The Rina Zaizov Division of Pediatric Hematology-Oncology, Schneider Children's Medical Center, Petach Tikva, Israel.
Felsenstein Medical Research Center, Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel.

Ruth Lubin (R)

The Institute of Biomedical and Oral Research, Hebrew University, Jerusalem, Israel.

Odeya David (O)

Pediatric Endocrinology Unit, Soroka University Medical Center, Beer Sheva, Israel.
Pediatric Ambulatory Center, Soroka University Medical Center, Beer Sheva, Israel.
Joyce and Irving Goldman Medical School, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel.

Ifat Geron (I)

The Rina Zaizov Division of Pediatric Hematology-Oncology, Schneider Children's Medical Center, Petach Tikva, Israel.
Felsenstein Medical Research Center, Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel.

Elimelech Okon (E)

Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Idit Hazan (I)

The Institute of Biomedical and Oral Research, Hebrew University, Jerusalem, Israel.

Marketa Zaliova (M)

Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine of Charles University Prague and University Hospital Motol, Prague, Czech Republic.

Gil Amarilyo (G)

Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Pediatric Rheumatology Unit, Schneider Children's Medical Center, Petach Tikva, Israel.

Yehudit Birger (Y)

The Rina Zaizov Division of Pediatric Hematology-Oncology, Schneider Children's Medical Center, Petach Tikva, Israel.
Felsenstein Medical Research Center, Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel.

Yael Borovitz (Y)

Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Institute of Nephrology, Schneider Children's Medical Center, Petach Tikva, Israel.

Dafna Brik (D)

The Rina Zaizov Division of Pediatric Hematology-Oncology, Schneider Children's Medical Center, Petach Tikva, Israel.

Arnon Broides (A)

Pediatric Ambulatory Center, Soroka University Medical Center, Beer Sheva, Israel.
Joyce and Irving Goldman Medical School, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel.
Pediatric Immunology Clinic, Soroka University Medical Center, Beer Sheva, Israel.

Sarit Cohen-Kedar (S)

Felsenstein Medical Research Center, Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel.
Division of Gastroenterology, Rabin Medical Center, Petach Tikva, Israel.

Liora Harel (L)

Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Pediatric Rheumatology Unit, Schneider Children's Medical Center, Petach Tikva, Israel.

Eyal Kristal (E)

Pediatric Ambulatory Center, Soroka University Medical Center, Beer Sheva, Israel.
Joyce and Irving Goldman Medical School, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel.
Pediatric Immunology Clinic, Soroka University Medical Center, Beer Sheva, Israel.

Daria Kozlova (D)

Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Department of Pathology, Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel.

Galina Ling (G)

Pediatric Ambulatory Center, Soroka University Medical Center, Beer Sheva, Israel.
Joyce and Irving Goldman Medical School, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel.

Mika Shapira Rootman (M)

Department of Radiology, Rambam Health Care Campus, Haifa, Israel.

Noa Shefer Averbuch (N)

Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Pediatric Genetics Clinic, Schneider Children's Medical Center of Israel, Petach Tikva, Israel.
The Jesse and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, Petach Tikva, Israel.

Shiri Spielman (S)

Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Department of Pediatrics A, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel.

Jan Trka (J)

Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine of Charles University Prague and University Hospital Motol, Prague, Czech Republic.

Shai Izraeli (S)

The Rina Zaizov Division of Pediatric Hematology-Oncology, Schneider Children's Medical Center, Petach Tikva, Israel.
Felsenstein Medical Research Center, Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel.
Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Beckman Research Institute, City of Hope, Duarte, CA.

Simon Yona (S)

The Institute of Biomedical and Oral Research, Hebrew University, Jerusalem, Israel.

Sarah Elitzur (S)

The Rina Zaizov Division of Pediatric Hematology-Oncology, Schneider Children's Medical Center, Petach Tikva, Israel.
Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH